Document:

Ex-4.11

Exhibit 4.11

WRIGHT MEDICAL GROUP, INC.

Restricted Stock Grant Agreement

Sales Representative

	 	 	 	 	 
	Award Granted to (“Grantee”):	 	Grant Date:	 	Number of Shares (“Shares”):
	«Name»
	 	«Date of Grant»
	 	«Shares»

          THIS RESTRICTED STOCK GRANT AGREEMENT (the “Agreement”) is made as of the Grant Date by and
between Wright Medical Group, Inc., a Delaware corporation with its principal place of business at
5677 Airline Road, Arlington, Tennessee 38002 (the “Company”) and Grantee pursuant to the Wright
Medical Group, Inc. 1999 Equity Incentive Plan, as amended from time to time (the “Plan”) and which
is hereby incorporated by reference.

          WHEREAS, Grantee is associated with the Company or its affiliate as sales representative; and

          WHEREAS, the Compensation Committee of the Company’s Board of Directors (the “Committee”) has
authorized that Grantee be granted shares of the Company’s Common Stock (“Stock”) subject to the
restrictions stated below;

          NOW, THEREFORE, the parties agree as follows:

	1.	 	Grant of Stock. Subject to the terms and conditions of this Agreement and of the Plan, the
Company hereby grants to Grantee the Shares.
	 
	2.	 	Vesting Schedule. The interest of Grantee in the Shares shall vest as to one-fourth (1/4) of
the Shares on the first anniversary of the Grant Date, and as to an additional one-fourth (1/4)
on each succeeding anniversary date, so as to be 100% vested on the fourth anniversary
thereof, conditioned upon Grantee’s continued association with the Company as of each vesting
date. Notwithstanding the foregoing, the interest of Grantee in the Shares shall vest as to:

	 	2.1.	 	100% of the then unvested Shares upon a Change of Control. For purposes of this
Agreement a “Change of Control” shall mean the first to occur on or after the Grant Date of
any of the following:

(a) The acquisition by any individual, entity or group (within the meaning of Section
13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”)) (a “Person”) of beneficial ownership (within the meaning of Rule 13d-3
promulgated under the Exchange Act) of 50% or more (on a fully diluted basis) of either
(A) the then outstanding shares of Stock, taking into account as outstanding for this
purpose such Stock issuable upon the exercise of options or warrants, the conversion of
convertible stock or debt, and the exercise of any similar right to acquire such Stock
(the “Outstanding Company Common Stock”) or (B) the combined voting power of the then
outstanding voting securities of the Company entitled to vote generally in the election
of directors (the “Outstanding Company Voting Securities”); provided, however, that for
purposes of this subsection (a), the following acquisitions shall not constitute a
Change of Control: (x) any acquisition by the Company or any “affiliate” of the
Company, within the meaning of 17 C.F.R. § 230.405 (an “Affiliate”), (y) any acquisition
by any employee benefit plan (or related trust) sponsored or maintained by the Company
or any Affiliate, (z) any acquisition by any corporation or business entity pursuant to
a transaction which complies with clauses (A) and (B) of subsection (a) of this Section
2.1 (persons and entities described in clauses (x), (y), and (z) being referred to
herein as “Permitted Holders”);

(b) The consummation of a reorganization, merger or consolidation or sale or other
disposition of all or substantially all of the assets of the Company (a “Business
Combination”),

 

 

Restricted Stock Grant Agreement

Page 2

in each case, unless, following such Business Combination, (A) all or substantially all
of the individuals and entities who were the beneficial owners, respectively, of the
Outstanding Company Common Stock and Outstanding Company Voting Securities immediately
prior to such Business Combination beneficially own, directly or indirectly, more than
60% of, respectively, the then outstanding shares of common stock and the combined
voting power of the then outstanding voting securities entitled to vote generally in the
election of directors, as the case may be, of the corporation resulting from such
Business Combination (including, without limitation, a corporation which as a result of
such transaction owns the Company or all or substantially all of the Company’s assets
either directly or through one or more subsidiaries) in substantially the same
proportions as their ownership, immediately prior to such Business Combination, of the
Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case
may be, (B) no Person (excluding any Permitted Holder) beneficially owns, directly or
indirectly, 50% or more (on a fully diluted basis) of, respectively, the then
outstanding shares of common stock of the corporation resulting from such Business
Combination, taking into account as outstanding for this purpose such common stock
issuable upon the exercise of options or warrants, the conversion of convertible stock
or debt, and the exercise of any similar right to acquire such common stock, or the
combined voting power of the then outstanding voting securities of such corporation
except to the extent that such ownership existed prior to the Business Combination, and
(C) at least a majority of the members of the board of directors of the corporation
resulting from such Business Combination were members of the incumbent Board at the time
of the execution of the initial agreement providing for such Business Combination;

(c) The approval by the stockholders of the Company of a complete liquidation or
dissolution of the Company;

(d) The sale of at least 80% of the assets of the Company to an unrelated party, or
completion of a transaction having a similar effect; or

(e) The individuals who on the date of this Agreement constitute the Board of Directors
thereafter cease to constitute at least a majority thereof; provided that any person
becoming a member of the Board of Directors subsequent to the date of this Agreement and
whose election or nomination was approved by a vote of at least two-thirds of the
directors who then comprised the Board of Directors immediately prior to such vote shall
be considered a member of the Board of Directors on the date of this Agreement.

	 	2.2.	 	100% of the unvested Shares upon Grantee’s death.

	3.	 	Restrictions.

	 	3.1.	 	The Shares granted hereunder may not be sold, pledged or otherwise transferred until
the Shares become vested in accordance with this Agreement. The period of time between the
Grant Date and the date the Shares become vested is referred to as the “Restriction
Period.”
	 
	 	3.2.	 	If Grantee’s association with the Company is terminated, the balance of the Shares
subject to the provisions of this Agreement which have not vested at the time of Grantee’s
termination shall be forfeited by Grantee, and ownership transferred back to the Company.
	 
	 	3.3.	 	By accepting the Shares, Grantee represents and agrees for Grantee and Grantee’s
transferees (whether by will or the laws of descent and distribution) that:

(a) For the period commencing on the Grant Date and ending on the first anniversary of
the termination of Grantee’s service (such period is hereinafter referred to as the
“Covenant Period “), with respect to any geographic territories in which the Company is
engaged in business during the period for which Grantee provided service to the Company,
Grantee shall

 

 

 Restricted Stock Grant Agreement

Page 3

not participate or engage, directly or indirectly, for Grantee or on behalf of or in
conjunction with any person, partnership, corporation or other entity, whether as an
employee, agent, officer, director, stockholder, partner, joint venturer, investor or
otherwise, (other than a limited partner or stockholder of less than one percent of the
issued and outstanding limited partnership interests or stock of a publicly held
partnership or corporation whose gross assets exceed $1,000,000) in the distribution,
solicitation, promotion, manufacture, design, development, or sale of any medical
products or services competitive with products manufactured, marketed, or sold by the
Company or any of its subsidiaries or any medical products or services intended to be
manufactured, marketed, or sold by the Company of the same general type or function.

(b) Except with the Company’s prior written approval or as may otherwise be required by
law or legal process, Grantee shall not disclose any material or information which is
confidential to the Company or its subsidiaries and not in the public domain or
generally known in the industry, whether tangible or intangible, made available,
disclosed or otherwise known to Grantee as a result of Grantee’s service with the
Company.

(c) During the Covenant Period, Grantee shall not attempt to influence, persuade or
induce, or assist any other person in so persuading or inducing, any employee of the
Company or its subsidiaries to give up, or to not commence, employment or a business
relationship with the Company.

	 	3.4.	 	The Company shall have the right, but not the obligation, to purchase and acquire from
Grantee any or all of the Shares (the “Repurchased Shares”) if the Committee reasonably
determines that Grantee has violated the covenants set forth in this Agreement or Grantee’s
service is terminated or could have been terminated for Cause (as defined in the Plan).
The Company may exercise the right granted to it under this Section 3.4 by delivering
written notice to Grantee stating that the Company is exercising the repurchase right
granted to it under this Section 3.4. The delivery of such notice by the Company to
Grantee shall constitute a binding commitment of the Company to purchase and acquire all of
the Repurchased Shares. The total purchase price for the Repurchased Shares shall be
delivered to the Participant against delivery by Grantee of certificates evidencing the
Repurchased Shares no later than 30 days after the delivery of the election notice by the
Company. The price per share of the Repurchased Shares shall be the lesser of 1) the Fair
Market Value (as defined in the Plan) of each of the Repurchased Shares on the date of the
Company’s delivery of its written notice to Grantee or 2) the Fair Market Value of each of
the Repurchased Shares on the date that such shares vested to the Grantee without regard to
any election by the Grantee under Section 83(b) of the Internal Revenue Code of 1986, as
amended.
	 
	 	3.5.	 	The Company shall have the right, but not the obligation, to cancel any or all of the
Shares if the Committee reasonably determines that Grantee has violated the covenants set
forth in this Agreement. The Company may exercise the right granted to it under this
Section 3.5 by delivering a written notice to Grantee stating that the Company is
exercising the cancellation right granted to it under this Section 3.5.
	 
	 	3.6.	 	Notwithstanding anything in this Section 3 to the contrary, the Company shall not be
obligated to purchase any Stock at any time to the extent that the purchase would result in
a violation of any law, statute, rule, regulation, order, writ, injunction, decree or
judgment promulgated or entered by any Federal, state, local or foreign court or
governmental authority applicable to the Company or any of its property.
	 
	 	3.7.	 	The parties intend the restrictions in Section 3.3 to be completely severable and
independent, and any invalidity or unenforceabitliy of any one or more such restrictions
shall not render invalid or unenforceable any one or more restrictions.

 

 

Restricted Stock Grant Agreement

Page 4

	4.	 	Legend. All certificates representing any shares of Stock subject to the provisions of this
Agreement shall have endorsed thereon the following legend:

THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT
TO A
RESTRICTED STOCK GRANT AGREEMENT BETWEEN THE
COMPANY AND THE
REGISTERED HOLDER, A COPY OF WHICH IS
ON FILE AT THE PRINCIPAL
OFFICE OF THIS COMPANY.

	5.	 	Escrow. The certificate or certificates evidencing the Shares subject hereto shall be
delivered to and deposited with the Secretary of the Company as Escrow Agent in this
transaction. The Shares may also be held in a restricted book entry account in the name of
Grantee. Such certificates or such book entry shares are to be held by the Escrow Agent until
termination of the Restriction Period, when they shall be released by the Escrow Agent to
Grantee.
	 
	6.	 	Stockholder Rights. During the Restriction Period, Grantee shall have all the rights of a
stockholder with respect to the Shares except for the right to transfer the Shares as set
forth in Section 3 and except as set forth in Section 7. Accordingly, Grantee shall have the
right to vote the Shares and to receive any cash dividends paid to or made with respect to the
Shares.
	 
	7.	 	Changes in Stock. In the event that as a result of (i) any stock dividend, stock split or
other change in the Stock, or (ii) any merger or sale of all or substantially all of the
assets or other acquisition of the Company, and by virtue of any such change Grantee shall in
Grantee’s capacity as owner of unvested shares of Stock which have been awarded to Grantee
(the “Prior Stock”) be entitled to new or additional or different shares or securities, such
new or additional or different shares or securities shall thereupon be considered unvested
Shares and shall be subject to all of the conditions and restrictions which were applicable to
the Prior Stock pursuant to this Agreement.
	 
	8.	 	Permanent and Total Disability of Grantee. In the event of the permanent and total
disability of Grantee, any unpaid but vested Shares shall be paid to Grantee if legally
competent or to a legally designated guardian or representative if Grantee is legally
incompetent.
	 
	9.	 	Death of Grantee. In the event of Grantee’s death after the vesting date but prior to the
payment of the Shares, such Shares shall be paid to Grantee’s estate or designated
beneficiary.
	 
	10.	 	Taxes. Grantee understands that Grantee will recognize income for federal and, if
applicable, state income tax purposes in an amount equal to the amount by which the fair
market value of the Shares, as of the Grant Date or vesting date, as applicable, exceeds any
consideration paid by Grantee for such Shares. Grantee shall be liable for any and all taxes,
including withholding taxes, arising out of this grant or the vesting of Shares hereunder. By
accepting the Shares, Grantee covenants to report such income in accordance with applicable
federal and state laws. To the extent that the receipt of the Shares or the end of the
Restriction Period results in income to Grantee and withholding obligations of the Company,
including federal or state withholding obligations, Grantee agrees that the Company shall
retain and instruct a registered broker(s) to sell such number of Shares necessary to satisfy
the Company’s withholding obligations, after deduction of the broker’s commission, and the
broker shall remit to the Company the cash necessary in order for the Company to satisfy its
withholding obligations. Grantee covenants to execute any such documents as are requested by
the broker of the Company in order to effectuate the sale of the Shares and payment of the tax
obligations to the Company. The Grantee represents to the Company that, as of the date
hereof, he or she is not aware of any material nonpublic information about the Company or the
Shares. The Grantee and the Company have structured this Agreement to constitute a “binding
contract” relating to the sale of Shares pursuant to this Section, consistent with the
affirmative defense to liability under Section 10(b) of the Exchange Act under Rule 10b5-1(c)
promulgated under the Exchange Act.

 

 

Restricted Stock Grant Agreement

Page 5

	11.	 	Representations. By accepting the Shares, Grantee represents and warrants for Grantee and
Grantee’s transferees (whether by will or the laws of descent and distribution) that:

(a) The sale and marketing of the Company’s products by Grantee are Grantee’s primary
trade or business.

(b) During the most recently ended calendar year Grantee derived, and during the current
calendar year Grantee expects to derive, the majority of Grantee’s earned income from
the sales and marketing of the Company’s products.

	12.	 	Miscellaneous.

	 	12.1.	 	The Company shall not be required (i) to transfer on its books any shares of Stock of
the Company which have been sold or transferred in violation of any provisions set forth in
this Agreement, or (ii) to treat as owner of such shares or to accord the right to vote as
such owner or to pay dividends to any transferee to whom such shares shall have been so
transferred.
	 
	 	12.2.	 	The parties agree to execute such further instruments and to take such action as may
be reasonably necessary to carry out the intent of this Agreement.
	 
	 	12.3.	 	Any notice required or permitted hereunder shall be given in writing and shall be
deemed effectively given upon delivery to Grantee at the address of Grantee then on file
with the Company.
	 
	 	12.4.	 	Neither the Plan nor this Agreement nor any provisions under either shall be construed
so as to grant Grantee any right to remain associated with the Company or any of its
affiliates.
	 
	 	12.5.	 	This Agreement constitutes the entire agreement of the parties with respect to the
subject matter hereof.

	 	 	 	 	 	 	 
	AGREED AND ACCEPTED:
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	GRANTEE:	 	WRIGHT MEDICAL GROUP, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 

Jason P. Hood, Vice President,

General Counsel, and SecretaryEX-10.1

Exhibit 10.1

EMPLOYMENT AGREEMENT

     THIS
AGREEMENT, made as of June 17, 2008 (the “Commencement
Date”), by and between MICHAEL BAKER CORPORATION, a Pennsylvania corporation (the “Company”), and
BRADLEY L. MALLORY (the “Executive”).

W
I T N E S S E
T H:

     WHEREAS, the Company desires to retain the services of the Executive;

     WHEREAS, Executive possesses valuable knowledge and skills that will contribute to the
successful operation of the Company’s business;

     WHEREAS, the Executive is willing to be employed by the Company, upon the terms and subject to
the conditions hereinafter set forth; and

     WHEREAS, the Company and Executive have agreed to execute and deliver this Agreement in
consideration, among other things, of (i) the access Executive will have to confidential or
proprietary information of the Company, either existing or to be developed or to be acquired
hereafter by the Company, (ii) the willingness of the Company to provide valuable benefits to
Executive, and (iii) Executive’s receipt of compensation from time to time by the Company;

     NOW, THEREFORE, intending to be legally bound, the Company agrees to employ Executive, and
Executive hereby agrees to be employed by the Company, upon the following terms and conditions:

ARTICLE I

EMPLOYMENT

     1.01. Office. Executive is hereby employed as President and Chief Executive Officer
of the Company and in such capacity shall use his best energies and abilities in the performance of
his duties hereunder and as prescribed in the By-Laws of the Company and in the performance of such
other duties as may be reasonably assigned to him from time to time by the Board of Directors of
the Company (the “Board”).

     1.02. Term. Subject to the terms and provisions of Article II hereof, Executive’s
employment hereunder shall continue until the third anniversary of the Commencement Date unless
sooner terminated pursuant to Article II hereof or unless renewed or extended by mutual written
consent of the Company and the Executive.

     1.03. Base Salary. During the term of Executive’s employment hereunder, compensation
shall be paid to Executive by the Company at the rate of $430,000 per year (the annual “Base
Salary”), payable on regularly scheduled payroll dates established pursuant to the Company’s
standard payroll practices. The Base Salary shall compensate Executive for all services provided
to the Company, including serving as a director on the Board. The rate of compensation to be paid
to Executive may be adjusted upward annually for cost-of-living increases, subject to a maximum
increase of three percent per year, and by the Board in additional amounts at any time based upon
Executive’s contribution to the success of the Company and on such other factors as the Board shall
deem appropriate.

     1.04. Bonus Compensation. Executive will be eligible to receive incentive bonuses as
the Board of Directors in its sole discretion may determine from time to time to be

 

 

appropriate, subject to achievement of performance criteria in excess of targets established.
If earned, incentive bonuses shall be payable within 21/2 months following the end of the calendar
year in which the amounts are no longer subject to a substantial risk of forfeiture.

     1.05. Long-Term Incentive.

     (a) Award. On the Commencement Date Executive shall be granted stock appreciation
rights (“SARs”) relating to 40,000 shares of the Company’s Common Stock, which SARs will vest as
provided in subsection (b).

     (b) Vesting. Executive’s SARs will vest, contingent upon Executive’s continued
employment with the Company as President and Chief Executive Officer on the applicable vesting date
in accordance with the following schedule:

	 	(i)	 	10,000 will vest on the 18th month
anniversary of the Commencement Date;
	 
	 	(ii)	 	an additional 15,000 will vest on the
24th month anniversary of the Commencement Date; and
	 
	 	(iii)	 	an additional 15,000 will vest on the
36th month anniversary of the Commencement Date.

     (c) Forfeiture.

              (i) Termination prior to 24th month anniversary. In the event that Executive’s
employment as President and Chief Executive Officer is terminated before the 24th month
anniversary of the Commencement Date for any reason, any SARs, whether vested or unvested, will be
automatically forfeited without any compensation therefor or further action required by the
Company.

              (ii) Forfeiture between 24th month and 36th month anniversary.
In the event that Executive’s employment as President and Chief Executive Officer is terminated on
or after the 24th month anniversary of the Commencement Date and before the 36
th month anniversary of the Commencement Date (an “Early Termination”), the following
provisions shall apply:

	 	(x)	 	If the Early Termination is by the
Company without cause, any unvested SARs will be automatically
forfeited without any compensation therefor and without further
action required by the Company and any vested SARs shall be
payable as provided in subsection (d)(ii).
	 
	 	(y)	 	If the Early Termination is by the
Executive for any reason, by reason or death or disability or by
the Company for Cause, as defined in Section 2.03 hereof, any
SARs, whether vested or unvested, will be automatically forfeited
without any compensation therefor or further action required by
the Company.

-2-

 

     (d) Payment. Subject to subsection (e), the following provisions shall govern
payment for vested SARs.

               (i) Timing and Amount. If Executive is employed as President and Chief Executive
Officer on the 36th month anniversary of the Commencement Date, the Executive shall be
entitled to a payment for vested SARs on such date. Such payment shall be equal to the positive
difference, if any, between the fair market value of a share of the Company’s common stock on the
36 th month anniversary of the Commencement Date and the fair market value of a share of
the Company’s common stock on the Commencement Date, multiplied by the number of vested SARs;
provided, however, the maximum payment amount shall not exceed the lesser of $860,000 if all SARs
have vested, or a pro-rata portion thereof (based upon a maximum payment of $21.50 per SAR) if less
than all of the SARs have vested.

               (ii) Timing and Amount — Early Termination. If Executive is not employed as
President and Chief Executive Officer on the 36th month anniversary of the Commencement
Date and has experienced an Early Termination, the Executive shall be entitled to a payment for
vested SARs upon the 30 th day following the Executive’s separation from service;
provided, however, that, in the event Executive is a “specified employee” under Section 409A of the
Internal Revenue Code (the “Code”) at the time of separation from service, no such amount shall be
paid until the first day following the six-month anniversary of Executive’s separation from
service. Such payment shall be equal to the positive difference, if any, between the fair market
value of a share of the Company’s common stock on the date of the Executive’s separation from
service and the fair market value of a share of the Company’s common stock on the Commencement
Date, multiplied by the number of vested SARs; provided, however, the maximum payment amount shall
not exceed the lesser of $286,667 if all SARs have vested, or a pro-rata portion thereof (based
upon a maximum payment of $7.166675 per SAR) if less than all of the SARs have vested.

               (iii) Medium of Payment. Payment for vested SARs shall be made in cash, subject to
the Company’s discretion to make such payment in shares of the Company’s common stock under and
pursuant to the terms of a shareholder-approved equity incentive plan, based on the fair market
value of the shares on the date of payment as provided herein.

               (iv) Fair Market Value. For purposes of this Agreement, fair market value of a share
of the Company’s common stock shall be equal to the closing price of a share of the Company’s
common stock as of the date for which fair market value is to be determined, as reported in The
Wall Street Journal, or similar reliable publication relied upon by the Company in its discretion.
In the event that fair market value cannot be determined in such manner, it shall be determined in
good faith by the Board.

     (e) Forfeiture and Repayment. Any payment for SARs awarded hereunder, whether
already paid or due, is expressly conditioned upon the Company’s accurate financial reporting. Any
obligation or commitment to make any such payment for SARs will be terminated and any such payments
already made will be subject to restitution by the Executive if Company finances require material
correction or restatement or if Executive engages in conduct that is materially adverse to the
interests of the Company, including statutory violations, failure to comply with the Company’s
rules or regulations or fraud. The Board shall have the sole and exclusive discretion to determine
what constitutes such conduct, the material nature of any correction or restatement, the
circumstances related thereto and the amount of any payment.

     (f) The number of shares relating to the SARs and the fair market value thereof will be
subject to adjustment upon the occurrence of stock dividends, splits and other dilutive events as
provided in Annex A and determined by the Board in its discretion in order to avoid the dilution or
enlargement of Executive’s rights.

-3-

 

     1.06. Business Expenses. The Company shall reimburse Executive for all reasonable
business expenses incurred by Executive in connection with Executive’s employment from the
Commencement Date through the Executive’s separation from service, which reimbursement shall comply
with the Company’s normal policy. The expense reimbursements provided in this Section 1.06 shall
be payable within 30 days of the calendar month following the calendar month in which the expense
was incurred during the Executive’s employment, in accordance with the Company’s standard payroll
and reimbursement procedures with respect to such expense reimbursements. All reimbursement
payments with respect to expenses incurred within a particular year shall in any event be made no
later than the end of the Executive’s taxable year following the taxable year in which the expense
was incurred. The amount of reimbursable expenses incurred in one taxable year of the Executive
shall not affect the amount of reimbursable expenses in a different taxable year, and such
reimbursement shall not be subject to liquidation or exchange for another benefit.

     1.07. Executive Benefits. At all times during the term of Executive’s employment
hereunder, Executive shall be covered by such major medical or health benefit plans, pensions and
other benefits as are available generally to employees of the Company.

     1.08. Board Position. Executive shall be a Director of the Company and shall be
permitted to hold such position at all times during the term of Executive’s employment as President
and Chief Executive Officer hereunder, subject to shareholder vote and unless the Board determines
in its reasonable discretion that Executive’s holding of such position is not in the best interest
of the Company.

ARTICLE II

TERMINATION

     2.01. Disability. If during the term of Executive’s employment hereunder Executive
shall be prevented, in the reasonable opinion of the Board, from effectively performing all his
duties hereunder by reason of illness or disability which continues for at least 140 days, then the
Company may, by written notice to Executive, terminate Executive’s employment hereunder. Upon
delivery to Executive of such termination notice, together with payment of any salary accrued under
Section 1.03 hereof, and any amounts due pursuant to Section 1.06 or Section 1.07 hereof, all
obligations of the Company under Article I hereof shall forthwith terminate. The obligations of
Executive under Article IV hereof, other than Section 4.03, shall continue notwithstanding
termination of Executive’s employment pursuant to this Section 2.01.

     2.02. Death. If Executive dies during the term of his employment hereunder,
Executive’s employment hereunder shall terminate and all obligations of the Company hereunder,
other than any obligations with respect to the payment of accrued and unpaid salary under
Section 1.03 hereof and any amounts due pursuant to Section 1.06 or Section 1.07 hereof, shall
terminate.

     2.03. Company Termination. (a) For Cause. The Company may terminate
Executive’s employment hereunder for “Cause.” For purposes of this Agreement, the term “Cause”
shall mean: (i) any willful action which adversely affects, or is intended to adversely affect,
the Company or any person or entity affiliated therewith, or the business or property of the
foregoing, (ii) the commission of a felony (as determined by a plea or a finding of guilt in a
court of competent jurisdiction), (iii) failure or refusal of Executive to perform any material
duties hereunder or to obey any direction from the Board, which failure or refusal remains uncured
thirty (30) days following written notice to Executive specifying such failure or refusal or
(iv) any conduct contributing to, or any failure to correct deficiencies directly or indirectly

-4-

 

resulting in, financial restatements or irregularities. Any determination that a termination
of Executive’s employment is with or without Cause will be made by the Board or a committee thereof
in its good faith judgment reasonably exercised.

     Upon a conclusive determination by the Board or a committee of Cause, Executive shall be paid
any amounts accrued under Sections 1.03, 1.06 or 1.07 hereof, and Executive’s employment and all
obligations of the Company under Article I hereof shall forthwith terminate. The obligations of
Executive under Article IV hereof, other than Section 4.03, shall continue notwithstanding
termination of Executive’s employment pursuant to this Section 2.03(a).

     (b) Without Cause. Executive’s employment hereunder may be terminated at any time by
the Company without Cause. Termination by reason of disability or death as provided in
Sections 2.01 and 2.02 or any resignation by the Executive shall not be considered a termination by
the Company without Cause. Upon any such termination without Cause and the execution and delivery
by Executive of a separation and release agreement in the form provided by the Company, the Company
shall pay to Executive an amount equal to the sum of (i) his salary accrued as of the date of
termination and (ii) a severance payment equal to (x) two times the Executive’s annual Base Salary
in the case of a termination without Cause occurring before the 24th month anniversary
of the Commencement Date, or (y) one times Executive’s annual Base Salary in the case of a
termination without Cause occurring on or after the 24th month anniversary of the
Commencement Date and on or before the 36th month anniversary of the Commencement Date,
and (iii)  any amounts due but unpaid pursuant to Sections 1.05, 1.06 and 1.07. Executive’s
employment and all obligations of the Company under Article I hereof shall cease effective as of
the date of such termination, except with respect to any payments pursuant to the immediately
preceding sentence. The obligations of Executive under Article IV hereof, other than Section 4.03,
shall continue notwithstanding termination of Executive’s employment pursuant to this Section
2.03(b). Any severance payment by the Company to the Executive pursuant to subsection (ii) shall
be made in a lump sum on the 30th day following the Executive’s separation from service;
provided, however, that, in the event Executive is a “specified employee” under Section 409A of the
Code at the time of separation from service, no such amount shall be paid until the first day
following the six-month anniversary of Executive’s separation from service. Any salary accrued as
of the date of termination and payable pursuant to subsection (i) shall be paid on the next
regularly scheduled payroll date following termination and any amounts payable pursuant to
subsection (iii) shall be paid on the date otherwise provided herein or the date specified in the
underlying plan, policy or arrangement, as applicable.

     2.04 Non-Renewal. The Executive shall not be entitled to any severance or similar
payments based upon a termination of employment on or after the 36th month anniversary
of the Commencement Date, and any failure to renew or extend the terms of this Agreement shall not
be deemed to be a termination without Cause or other basis for payment of any severance or similar
amounts.

ARTICLE III

EXECUTIVE’S ACKNOWLEDGMENTS

     3.01. Confidential Information. Executive recognizes and acknowledges that:

     (a) in the course of Executive’s employment by the Company it will be necessary for Executive
to acquire information which could include, in whole or in part, information concerning the
Company’s sales, sales volume, sales methods, sales proposals, customers and prospective customers,
identity of customers and prospective customers, identity of key purchasing personnel in the employ
of customers and prospective customers, amount or kind of

-5-

 

customer’s purchases from the Company, the Company’s sources of supply, the Company’s computer
programs, system documentation, special hardware, product hardware, related software development,
the Company’s manuals, formulae, processes, methods, machines, compositions, ideas, improvements,
inventions or other confidential or proprietary information belonging to the Company or relating to
the Company’s affairs (collectively referred to herein as the “Confidential Information”);
provided, however, that Confidential Information does not include information which:

               (i) is or becomes generally available to the public other than as a result of a disclosure by
Executive,

               (ii)  was available to Executive on a non-confidential basis prior to its disclosure to
Executive by the Company or its representatives,

               (iii) becomes available to Executive on a non-confidential basis from a source other than the
Company or its representatives, provided that such source is not bound by a confidentiality
agreement or otherwise prohibited from transmitting the Confidential Information to Executive by a
contractual, legal or fiduciary obligation), or

               (iv) the Executive legally obtained knowledge of prior to his first contact with the Company;

     (b)  the Confidential Information is the property of the Company;

     (c)  the use, misappropriation or disclosure of the Confidential Information would constitute
a breach of trust and could cause irreparable injury to the Company; and

     (d)  it is essential to the protection of the Company’s good will and to the maintenance of
the Company’s competitive position that the Confidential Information be kept secret and that
Executive not disclose the Confidential Information to others or use the Confidential Information
to Executive’s own advantage or the advantage of others.

     3.02. Non-Solicitation and Non-Competition. As further detailed in Article IV hereof,
Executive further recognizes and acknowledges that it is essential for the proper protection of the
business of the Company that Executive be restrained (a) from soliciting or inducing any employee
of the Company to leave the employ of the Company, (b) from hiring or attempting to hire any
employee of the Company, (c) from soliciting the trade of or trading with the customers and
suppliers of the Company for any Competing Business purpose, as defined in Section 4.05 hereof, and
(d) from competing against the Company for a reasonable period (as described in Section 4.05
hereof) following the termination of Executive’s employment with the Company.

     3.03. Work Made for Hire. Executive further recognizes and understands that his
duties at the Company may include the preparation of materials, including written or graphic
materials, and that any such materials conceived or written by him shall be done as “work made for
hire” as defined and used in the Copyright Act of 1976, 17 USC § 1 et seq. In the event of
publication of such materials, Executive understands that because the work is a “work made for
hire”, the Company will solely retain and own all rights in said materials, including right of
copyright, and that the Company may, at its discretion, on a case-by-case basis, grant Executive
by-line credit on such materials as the Company may deem appropriate.

-6-

 

ARTICLE IV

EXECUTIVE’S COVENANTS AND AGREEMENTS

     4.01. Non-Disclosure of Confidential Information. Executive agrees to hold and
safeguard the Confidential Information in trust for the Company, its successors and assigns and
agrees that he shall not, without the prior written consent of the Company, misappropriate or
disclose or make available to anyone for use outside the Company’s organization at any time, either
during his employment with the Company or subsequent to the termination of his employment with the
Company for any reason, including without limitation termination by the Company for Cause or
without Cause, any of the Confidential Information, whether or not developed by Executive, except
as required in the performance of Executive’s duties to the Company.

     4.02. Disclosure of Works and Inventions/Assignment of Patents. Executive shall
disclose promptly to the Company or its nominee any and all works, inventions, discoveries and
improvements authored, conceived or made by Executive during the period of employment and related
to the business or activities of the Company, and hereby assigns and agrees to assign all his
interest therein to the Company or its nominee. Whenever requested to do so by the Company,
Executive shall execute any and all applications, assignments or other instruments which the
Company shall deem necessary to apply for and obtain Letters Patent or Copyrights of the United
States or any foreign country or to otherwise protect the Company’s interest therein. Such
obligations shall continue beyond the termination of employment with respect to works, inventions,
discoveries and improvements authored, conceived or made by Executive during the period of
employment, and shall be binding upon Executive’s assigns, executors, administrators and other
legal representatives.

     4.03. Duties. Executive agrees to be a loyal employee of the Company. Executive
agrees to devote his best efforts full time to the performance of his duties for the Company, to
give proper time and attention to furthering the Company’s business, and to comply with all rules,
regulations and instruments established or issued by the Company. Executive further agrees that
during the term of this Agreement, Executive shall not, directly or indirectly, engage in any
business which would detract from Executive’s ability to apply his best efforts to the performance
of his duties hereunder. Executive also agrees that he shall not usurp any corporate opportunities
of the Company.

     4.04. Return of Materials. Upon the termination of Executive’s employment with the
Company for any reason, including without limitation termination by the Company for Cause or
without Cause, Executive shall promptly deliver to the Company all correspondence, drawings,
blueprints, manuals, letters, notes, notebooks, reports, flow-charts, programs, proposals and any
documents concerning the Company’s customers or concerning products or processes used by the
Company and, without limiting the foregoing, will promptly deliver to the Company any and all other
documents or materials containing or constituting Confidential Information.

     4.05. Restrictions on Competition. Executive covenants and agrees that during the
period of Executive’s employment hereunder and for a period of one year following the termination
of Executive’s employment, including without limitation termination by the Company for Cause or
without Cause, Executive shall not, in the United States of America, or in any other country in
which the Company has done business at any time during the last 12 months immediately prior to
termination of Executive’s employment with the Company, engage, directly or indirectly, whether as
principal or as agent, officer, director, employee, consultant, shareholder, or otherwise, alone or
in association with any other person, corporation or other entity, in any Competing Business. For
purposes of this Agreement, the term “Competing

-7-

 

Business” shall mean: any person, corporation or other entity engaged in the business of
selling or attempting to sell any product or service which is the same as or similar to products or
services sold by the Company within one year prior to termination of Executive’s employment
hereunder or contemplated at such time to be sold by the Company.

     4.06. Non-Solicitation of Customers and Suppliers. Executive agrees that during his
employment with the Company he shall not, directly or indirectly, solicit the trade of, or trade
with, any customer, prospective customer, supplier, or prospective supplier of the Company for any
business purpose other than for the benefit of the Company. Executive further agrees that for one
year following termination of his employment with the Company, including without limitation
termination by the Company for Cause or without Cause, Executive shall not, on behalf of any
Competing Business, directly or indirectly, solicit the trade of, or trade with, any customers or
suppliers, or prospective customers or suppliers, of the Company.

     4.07. Non-Solicitation of Employees. Executive agrees that, during his employment
with the Company and for one year following termination of Executive’s employment with the Company,
including without limitation termination by the Company for Cause or without Cause, Executive shall
not, directly or indirectly, solicit or induce, or attempt to solicit or induce, any employee of
the Company to leave the Company for any reason whatsoever, or hire any employee of the Company.

     4.08. Work Made for Hire. Executive agrees that in the event of publication by
Executive of written or graphic materials relating to the Company’s business, the Company will
retain and own all rights in said materials, including right of copyright.

ARTICLE V

EXECUTIVE’S REPRESENTATIONS AND WARRANTIES

     5.01. No Prior Agreements. Executive represents and warrants that he is not a party
to or otherwise subject to or bound by the terms of any contract, agreement or understanding which
in any manner would limit or otherwise affect his ability to perform his obligations hereunder,
including without limitation any contract, agreement or understanding containing terms and
provisions similar in any manner to those contained in Article IV hereof. Executive further
represents and warrants that his employment with the Company will not require him to disclose or
use any confidential information belonging to prior employers or other persons or entities.

     5.02. Executive’s Abilities. Executive represents that his experience and
capabilities are such that the provisions of Article IV will not prevent him from earning his
livelihood, and acknowledges that it would cause the Company serious and irreparable injury and
cost if Executive were to use his ability and knowledge in competition with the Company or to
otherwise breach the obligations contained in Article IV.

     5.03. Remedies. In the event of a breach by Executive of the terms of this Agreement,
the Company shall be entitled, if it shall so elect, to institute legal proceedings to obtain
damages for any such breach, or to enforce the specific performance of this Agreement by Executive
and to enjoin Executive from any further violation of this Agreement and to exercise such remedies
cumulatively or in conjunction with all other rights and remedies provided by law. Executive
acknowledges, however, that the remedies at law for any breach by him of the provisions of this
Agreement may be inadequate and that the Company shall be entitled to injunctive relief against him
in the event of any breach.

-8-

 

ARTICLE VI

MISCELLANEOUS

     6.01. Authorization to Modify Restrictions. It is the intention of the parties that
the provisions of Article IV hereof shall be enforceable to the fullest extent permissible under
applicable law, but that the unenforceability (or modification to conform to such law) of any
provision or provisions hereof shall not render unenforceable, or impair, the remainder thereof.
If any provision or provisions hereof shall be deemed invalid or unenforceable, either in whole or
in part, this Agreement shall be deemed amended to delete or modify, as necessary, the offending
provision or provisions and to alter the bounds thereof in order to render it valid and
enforceable.

     6.02. Tolling Period. If a court determines that Executive is in breach of
obligations contained in Sections 4.05, 4.06 or 4.07 of Article IV hereof, those obligations shall
be extended by the length of time during which Executive shall have been in breach of any of the
provisions of such Article IV.

     6.03. Entire Agreement. This Agreement represents the entire agreement of the parties
and may be amended only by a writing signed by each of them.

     6.04. Governing Law. This Agreement shall be governed by and construed in accordance
with the laws of the Commonwealth of Pennsylvania.

     6.05. Consent to Jurisdiction. Each of the Company and Executive hereby irrevocably
submits to the personal jurisdiction of the United States District Court for the Western District
of Pennsylvania or the Court of Common Pleas of Allegheny County, Pennsylvania in any action or
proceeding arising out of or relating to this Agreement, and each of the Company and Executive
hereby irrevocably agrees that all claims in respect of any such action or proceeding may be heard
and determined in either such court.

     6.06. Service of Process. Each of the Company and Executive hereby irrevocably
consents to the service of any summons and complaint and any other process which may be served in
any action or proceeding arising out of or related to this Agreement brought in the United States
District Court for the Western District of Pennsylvania or the Court of Common Pleas of Allegheny
County, Pennsylvania by the mailing by certified or registered mail of copies of such process to
such party at its or his address as set forth on the signature page hereof.

     6.07. Venue. Each of the Company and Executive hereby irrevocably waives any
objection which it or he now or hereafter may have to the laying of venue of any action or
proceeding arising out of or relating to this Agreement brought in the United States District Court
for the Western District of Pennsylvania or the Court of Common Pleas of Allegheny County,
Pennsylvania and any objection on the ground that any such action or proceeding in either of such
Courts has been brought in an inconvenient forum. Nothing in this Section 6.07 shall affect the
right of the Company to bring any action or proceeding against Executive in the courts of other
jurisdictions where Executive may be found or served with process.

     6.08. Remedies. If either the Company or Executive prevails in a proceeding for
injunctive relief, the non-prevailing party agrees that the prevailing party, in addition to other
relief, shall be entitled to reasonable attorneys’ fees, costs and the expenses of litigation
incurred by the prevailing party in securing the relief granted by the Court.

     6.09. Agreement Binding. The obligations of Executive under this Agreement shall
continue after the termination of his employment with the Company for any reason, with or

-9-

 

without Cause, and shall be binding on his heirs, executors, legal representatives and assigns
and shall inure to the benefit of any successors and assigns of the Company, and the obligations of
the Company hereunder shall be binding upon the successors and assigns of the Company and shall
inure to the benefit of any successors of Executive.

     6.10. Counterparts, Section Headings. This Agreement may be executed in any number of
counterparts, each of which shall be deemed to be an original, but all of which together shall
constitute one and the same instrument. The section headings of this Agreement are for convenience
of reference only and shall not affect the construction or interpretation of any of the provisions
hereof.

     6.11. Compliance with Code Section 409A. To the extent applicable, it is intended
that this Agreement comply with the provisions of Section 409A of the Code, so that the income
inclusion provisions of Section 409A(a)(1) do not apply to the Executive. This Agreement shall be
administered in a manner consistent with this intent, and any provision that would cause the
Agreement to fail to satisfy Section 409A of the Code shall have no force and effect until amended
to comply with Section 409A of the Code (which amendment may be retroactive to the extent permitted
by Section 409A of the Code and may be made by the Company without the consent of the Executive).
The term “termination,” when used in the context of a condition to, or timing of, payment hereunder
shall be interpreted to mean a “separation from service” as that term is used in Section 409A of
the Code.

EXECUTIVE ACKNOWLEDGES THAT HE HAS READ AND UNDERSTANDS THE FOREGOING PROVISIONS AND THAT SUCH
PROVISIONS ARE REASONABLE AND ENFORCEABLE.

-10-

 

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement or caused this Agreement
to be executed the day and year first above written.

	 	 	 	 	 	 	 	 	 
	Witness:

	 	 	 	 	 	 	 	 
	 
	 
	 	 	 	 	 	 	 	 
	/s/
Diane E. Bemis 

	 	 	 	 	 	/s/ Bradley L. Mallory	 	 
	 	 	 	 	 	 	 
	 

	 	 	 	 	 	Bradley L. Mallory	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	Address:	 	1008 Country Club Road 	 	 
	 

	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	Camp Hill, PA 17011 	 	 
	 

	 	 	 	 	 	 	 	 

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	MICHAEL BAKER CORPORATION	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	By: 	 	/s/ Richard L. Shaw 	 	 
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	Richard L. Shaw, Chairman	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	Address:	 	100 Airside Drive	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	Moon Township, PA 15108	 	 

-11-

 

ANNEX A

Adjustment and Substitution of Shares

     If a dividend or other distribution shall be declared upon the Common Stock payable in shares
of Common Stock, then the number of shares of Common Stock then represented by any outstanding SARs
shall be adjusted by adding thereto the number of shares of Common Stock which would have been
related thereto if such shares had been outstanding on the date fixed for determining the
shareholders entitled to receive such stock dividend or distribution.

     If the outstanding shares of Common Stock shall be changed into or exchangeable for a
different number or kind of shares of stock or other securities of the Company or another
corporation, or cash or other property, whether through reorganization, reclassification,
recapitalization, stock split-up, combination of shares, merger or consolidation, then there shall
be substituted for each share of Common Stock represented by any then outstanding SARs the number
and kind of shares of stock or other securities or the cash or other property into which each
outstanding share of the Common Stock shall be so changed or for which each such share shall be
exchangeable.

     In case of any adjustment or substitution as provided for in this Annex A, the initial
aggregate fair market value for all shares represented by then outstanding SARs prior to such
adjustment or substitution shall be the initial aggregate fair market value for all shares of stock
or other securities (including any fraction), cash or other property to which such shares shall
have been adjusted or which shall have been substituted for such shares. Any new fair market value
per share or other unit shall be carried to at least three decimal places with the last decimal
place rounded upwards to the nearest whole number.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}]]